Company: AEMD
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001683168-25-008271
Chunk: 13

Company: AETHLON MEDICAL INC
Filing Date: 2025-11-12
Form: 10-Q
Item: Item 1
Chunk 13
---
 or after April 1, 2025. The Company maintains a full valuation allowance against its deferred assets and
does not have current income tax expense nor material income taxes paid. While the Company is evaluating the impact of this new standard
on its income tax disclosures, it does not expect the adoption of ASU 2023-09 to have material impact on its consolidated financial statements,
as the amendments relate to disclosures only.

In November
2024, the FASB issued Accounting Standards Update 2024-03, Income Statement—Reporting Comprehensive Income—Expense
Disaggregation Disclosures (“ASU 2024-03”), which requires public business entities to provide enhanced annual and
interim disclosures that disaggregate specified income statement expense categories. ASU 2024-03 is effective for annual periods beginning
after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027, with early adoption permitted. In
January 2025 the FASB issued Accounting Standards Update 2025-01, Income Statement — Reporting Comprehensive Income
— Expense Disaggregation Disclosures (Subtopic 220-40): Clarifying the Effective Date, to clarify effective dates of in
ASU 2024-03. The Company is currently evaluating the potential impact of this guidance on its disclosures.

In March
2024, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update No. 2024-02, Codification Improvements—Amendments
to Remove References to the Concepts Statements (“ASU 2024-02”). ASU 2024-02 eliminates various references to the
FASB’s Concepts Statements from the FASB Accounting Standards Codification in order to clarify that the Codification represents
the authoritative source of generally accepted accounting principles (GAAP) in the United States. The amendments do not alter existing
accounting requirements. The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after
December 15, 2024, and early adoption is permitted. This ASU is not expected to have a material impact on the Company’s consolidated
financial statements or disclosures. 

5. EQUITY TRANSACTIONS IN THE SIX MONTHS ENDED SEPTEMBER 30, 2025

October
2025 Reverse Stock Split

On October 16, 2025,
the Company implemented a 1-for-10 reverse stock